<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247971</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104326</org_study_id>
    <nct_id>NCT04247971</nct_id>
  </id_info>
  <brief_title>Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma</brief_title>
  <official_title>Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain understanding of mechanisms whereby bariatric surgery
      modulates pulmonary inflammation and pulmonary microbiome composition and how these changes
      direct the pathobiology of human obese asthma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in leptin levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in adiponectin levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-8 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-6 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cystatin-c levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-17 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-1beta levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TNF-α levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in YKL-40 levels</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced expiratory volume</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced vital capacity</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by fractional concentration of exhaled nitro oxide</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by FEV1/FVC</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function as measured by forced expiratory flow</measure>
    <time_frame>Baseline (2 weeks before surgery), 30 days post-surgery, 3 months post-surgery</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <description>Obese adults (BMI&gt;or= 30) between the ages of 21-60 with an initial asthma diagnosis at &lt;12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
    <description>Obese adults (BMI &gt; or = 30) between the ages of 21-60 with an initial asthma diagnosis at &gt;12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <description>Obese adults (BMI &gt; or = 30) between the ages of 21-60 with no asthma diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>23 ml of blood collected</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sputum collection</intervention_name>
    <description>Induced sputum sample collected</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary function test</intervention_name>
    <description>Pulmonary function testing</description>
    <arm_group_label>Obese non-asthmatics</arm_group_label>
    <arm_group_label>Obese, early-onset asthmatics</arm_group_label>
    <arm_group_label>Obese, late-onset asthmatics</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of 15-20 obese, early-onset asthmatic, 15-20 obese, late-onset asthmatic, and 15-20
        obese non-asthmatic subjects will be recruited. Subjects in each group will undergo an
        initial screening visit (V0) to establish the subject groups according to asthma diagnosis,
        asthma onset age and type of scheduled surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Asthma Subjects

          -  Outpatient adults of either sex 21-60 years of age with an initial asthma diagnosis at
             &lt; 12 years of age (early-onset) or &gt;12 years of age (late-onset), as defined by the
             NHLBI NAEPP guidelines (17).

          -  Subjects with obesity (BMI ≥ 30 kg/m2).

          -  Physician diagnosis of asthma.

          -  Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve
             gastrectomy or duodenal switch) and receiving care within the Duke Health System.

        FEV1 within acceptable limits (&gt;45% predicted before and &gt;55% predicted after,
        bronchodilator administration).

          -  Relatively healthy subjects able to undergo sputum induction without complications.

          -  Willing and able to give informed consent and adhere to visit/protocol schedules.

          -  Read and write in English.

        Non-Asthma Control Subjects

          -  Outpatient adults of either sex 21-60 years of age.

          -  Subjects with obesity (BMI ≥ 30).

          -  Eligible and scheduled for bariatric surgery (Roux-en-Y gastric bypass, sleeve
             gastrectomy or duodenal switch) at Duke Regional Hospital and receiving care at the
             Duke Metabolic and -Weight Loss Surgery Center.

          -  Normal lung function.

          -  No clinical history of atopy.

          -  No significant medical or psychological issues.

          -  Healthy subjects able to undergo sputum induction without complications.

          -  Willing and able to give informed consent and adhere to visit/protocol schedules.

          -  Read and write in English.

        Exclusion Criteria:

          -  Children &lt; 21 years of age.

          -  Inpatient status.

          -  Ineligibility or not scheduled for bariatric surgery at the Duke Metabolic and Weight
             Loss Surgery Center.

          -  FEV1 is less than 45% predicted before, or less than 55% predicted after,
             bronchodilator administration.

          -  Upper or lower respiratory tract infection within one month of the study.

          -  Use of systemic corticosteroids within four weeks of study.

          -  Smoking (tobacco, e-cigarette, vaping or inhaled drugs) history &gt; 5 pack years or
             smoking or vaping within the previous six months.

          -  Significant non-asthma pulmonary disease (stable obstructive sleep apnea is not
             excluded).

          -  An ED visit or inpatient admission for a primary respiratory diagnosis within 60 days
             of enrollment.

          -  Poorly controlled concomitant conditions that pose additional procedure risk as
             determined by the investigator.

          -  All patients on anticoagulants.

          -  Uncontrolled sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Guerron Cruz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delinda Phillips</last_name>
    <phone>919-684-8631</phone>
    <email>delinda.phillips@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Delinda Phillips</last_name>
      <phone>919-684-8631</phone>
      <email>delinda.phillips@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

